摘要目的 建立人类慢性粒细胞白血病(CML)细胞系K562细胞在伊马替尼(Imatinib mesylate)处理前、后的DNA损伤模型,探讨伊马替尼对K562细胞的DNA损伤修复功能的影响.方法 用噻唑蓝(MTT)法确定伊马替尼预处理K562细胞的浓度;用免疫印迹法(Western blot)检测伊马替尼处理后K562细胞BCR/ABL的磷酸化状态,以反映BCR-ABL酪氨酸激酶活性受抑制情况;用彗星实验检测不同浓度过氧化氢(H2O2)诱导的K562细胞、伊马替尼预处理K562细胞的DNA损伤模型;用彗星实验对各组细胞在DNA损伤后的修复进行动态观测.结果 MTT实验结果显示,伊马替尼预处理K562细胞的最佳终浓度为1 μmol/L,作用时间24 h;Western blot实验结果显示,该浓度的伊马替尼可有效抑制BCR/ABL融合蛋白第177位酪氨酸激酶磷酸化,密度比为0.100±0.018,与对照组(0.425±0.039)相比,降低了(77.11±5.59)%,差异有统计学意义(t=4.57,P＜0.05);彗星实验确定了各组细胞DNA损伤模型的建立条件,采用10 μmol/L终浓度的H2O2对K562细胞和伊马替尼预处理后K562细胞进行染毒,H2O2作用温度和时间为4℃、10 min.修复结果显示,经伊马替尼预处理的K562细胞修复时间为120 min,与未处理组修复时间60 min相比,前者DNA损伤修复时间明显延长(F=97.79,P＜0.05).结论 本研究建立了伊马替尼处理前、后的白血病K562细胞的DNA损伤模型,BCR/ABL融合蛋白的酪氨酸激酶抑制剂伊马替尼能减弱K562细胞的DNA损伤后修复能力.

abstractsObjeetive To construct the cell DNA damage models for the human CML K562 cell line before or after imarlnib mesylate treatment and observe the repairing process dynamically for investigating the iniluence of imatinib mesylate on the repair function of K562 cells after cell DNA danlage.Methods The MTT assay was used to estimate the optimal pretreatment concentration of imatinib mesylate in K562 cells and Western blot was employed to evaluate the phosphorylation status in K562 cells after imatinib mesylate treatment to estimate BCR/ABL tyrosine kinase inhibition by imatinib mesylate.The comet assay was used to detect the DNA damage induced by hydrogen peroxide at various concentrations in K562 cells with or without the pretreatment of imatinib mesylate.A dynamic observation on the repairing process after cell DNA damage was made by the comet assay.Results The pretreatment by imatinib mesylate for K562 cells was optimized to be at a final concentration of 1 μmol/L for 24 h as revealed by the MTT assay additionly imatinib mesylate treatment at this concentration could effectively inhibit the phosphorylation of the BCR-ABL fusion protein at Tyr177(Deusityrate 0.100±0.018).When compared with the control group(Deusityrate 0.425±0.039),the BCR/ABL phosphorylation at Tyr177 was significantly decreased by (77. 11±5.59) % (t=4. 57,P＜0. 05). The cell DNA damage models for both imatinib mesylate-nontreated and imatinib mesylate-pretreated K562 cell groups were constructed with hydrogen peroxide treatment at a final concentration of 10 μmol/L for 10 min at 4℃ as confirmed by the comet assay. When compared with the control imatinib mesylatenontreatod K562 cell group,the time duration required for the DNA repair in imatinib mesylate-pretreated K562 cell group was significantly prolonged (F= 97.79,P＜0. 05 ). Conclusions The cell DNA damage models for the leukemic K562 cell groups before or after imatinib mesylate treatment were successfully constructed and the tyrosine kinase inhibitor imatinib mesylate for BCR/ABL fusion protein was revealed to attenuate the DNA repair capacity of the K562 cells after DNA damage.